{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:46:24Z","timestamp":1791146784104,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.bcmd.2013.10.002","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T18:46:14Z","timestamp":1384454774000},"page":"134-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression"],"prefix":"10.1016","volume":"52","author":[{"given":"Julieta","family":"Panero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Stanganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Arbelbide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorotea Beatriz","family":"Fantl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Kohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n","family":"Garc\u00eda Rivello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel A.","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Slavutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2013.10.002_bb0005","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0380","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance preceding multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0015","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.4049\/jimmunol.169.8.4213","article-title":"The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity","volume":"169","author":"Mingens Wols","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0385","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1038\/bcj.2012.38","article-title":"Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?","volume":"2","author":"Noll","year":"2012","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0025","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.2008.07252.x","article-title":"Galectin-1 supports the survival of CD45RA(\u2212) primary myeloma cells in vitro","volume":"142","author":"Abroun","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0030","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrg1656","article-title":"Telomeres and human disease: ageing, cancer and beyond","volume":"6","author":"Blasco","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0285","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1138596","article-title":"Protein composition of catalytically active human telomerase from immortal cells","volume":"315","author":"Cohen","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0290","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1165357","article-title":"A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis","volume":"323","author":"Venteicher","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0045","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/cncr.10472","article-title":"Clinical significance of telomerase activity in multiple myeloma","volume":"94","author":"Shiratsuchi","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0050","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1054\/bjoc.2000.1655","article-title":"Telomerase activity in plasma cell dyscrasias","volume":"84","author":"Xu","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0055","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(04)17371-6","article-title":"New therapeutic targets in multiple myeloma","volume":"364","author":"Gahrton","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0295","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1182\/blood-2002-11-3451","article-title":"Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival","volume":"101","author":"Wu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2119\/molmed.2010.00057","article-title":"Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"16","author":"Panero","year":"2010","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0070","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbrc.2004.10.137","article-title":"Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines","volume":"325","author":"Guilleret","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.gene.2012.01.095","article-title":"Regulation of the human catalytic subunit of telomerase (hTERT)","volume":"498","author":"Daniel","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev.genet.41.110306.130350","article-title":"How shelterin protects mammalian telomeres","volume":"42","author":"Palm","year":"2008","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0085","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nsmb867","article-title":"Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection","volume":"11","author":"Lei","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0090","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1128\/MCB.25.2.808-818.2005","article-title":"Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro","volume":"25","author":"Kelleher","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.embor.7400314","article-title":"How the human telomeric proteins TRF1 and TRF2 recognize telomeric DNA: a view from high-resolution crystal structures","volume":"6","author":"Court","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0100","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1038\/emboj.2009.275","article-title":"Human RAP1 inhibits non-homologous end joining at telomeres","volume":"28","author":"Sarthy","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0105","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.4161\/cc.9.20.13579","article-title":"Taking apart Rap1: an adaptor protein with telomeric and non-telomeric functions","volume":"9","author":"Kabir","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0110","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1111\/j.1582-4934.2012.01628.x","article-title":"Expression profile of telomere-associated genes in multiple myeloma","volume":"16","author":"D\u00edaz de la Guardia","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0115","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2010","journal-title":"Br. J. Haemtol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0300","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0305","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.bjc.6601112","article-title":"Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation","volume":"89","author":"Klapper","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0375","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1182\/blood-2007-09-111245","article-title":"Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia","volume":"111","author":"Poncet","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0315","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.3748\/wjg.v10.i23.3514","article-title":"Real-time determination of human telomerase reverse transcriptase mRNA in gastric cancer","volume":"10","author":"Hu","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0145","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1034\/j.1600-0609.2003.00157.x","article-title":"Telomere shortening in patients with plasma cell disorders","volume":"71","author":"Cottliar","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-009-0818-3","article-title":"DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance","volume":"89","author":"Stanganelli","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0155","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1073\/pnas.0706017104","article-title":"The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma","volume":"104","author":"Juszczynski","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0320","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ni.1772","article-title":"Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10","volume":"10","author":"Ilarregui","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0325","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.cub.2004.08.052","article-title":"A dynamic molecular link between the telomere length regulator TRF1 and the chromosome end protector TRF2","volume":"14","author":"Houghtaling","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0330","doi-asserted-by":"crossref","first-page":"11874","DOI":"10.1073\/pnas.0605303103","article-title":"A critical role for TPP1 and TIN2 interaction in high-order telomeric complex assembly","volume":"103","author":"O'Connor","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0959-437X(99)00047-7","article-title":"A critical role for telomeres in suppressing and facilitating carcinogenesis","volume":"10","author":"Artandi","year":"2000","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0180","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00432-010-0795-x","article-title":"Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer","volume":"136","author":"Hu","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0185","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/ijc.22026","article-title":"Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia","volume":"119","author":"Bellon","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0335","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2010-07-295774","article-title":"Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation","volume":"118","author":"Augereau","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0195","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/djg011","article-title":"Telomere dysfunction: a potential cancer predisposition factor","volume":"95","author":"Wu","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0340","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.exphem.2007.03.009","article-title":"Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis","volume":"35","author":"Widmann","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0345","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/jclinpath-2011-200211","article-title":"Silencing of the hPOT1 gene by RNA inference promotes apoptosis and inhibits proliferation and aggressive phenotype of gastric cancer cells, likely through up-regulating PinX1 expression","volume":"64","author":"Wan","year":"2001","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0350","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng.2584","article-title":"POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia","volume":"45","author":"Ramsay","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0355","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0301-472X(01)00760-3","article-title":"CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia","volume":"30","author":"Bechter","year":"2002","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/35049533","article-title":"DNA methylation in health and disease","volume":"1","author":"Robertson","year":"2000","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0360","first-page":"537","article-title":"Methylation of the human telomerase gene CpG island","volume":"60","author":"Dessain","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0230","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ijc.10593","article-title":"Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity","volume":"101","author":"Guilleret","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0235","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/nar\/gkl1125","article-title":"Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene","volume":"35","author":"Renaud","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0240","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood.V120.21.3489.3489","article-title":"Mechanisms of telomere maintenance dysfunction in B-chronic lymphocytic leukemia through CpG island methylation","volume":"120","author":"Auchter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0245","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.immuni.2012.03.004","article-title":"Regulatory circuits mediated by lectin\u2013glycan interactions in autoimmunity and cancer","volume":"36","author":"Rabinovich","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0250","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1535-6108(04)00024-8","article-title":"Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege","volume":"5","author":"Rubinstein","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0365","doi-asserted-by":"crossref","first-page":"15975","DOI":"10.1073\/pnas.0603883103","article-title":"Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy","volume":"103","author":"Thijssen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0260","first-page":"74","article-title":"Expression of galectin-1 in malignant tumors","volume":"31","author":"Demydenko","year":"2009","journal-title":"Exp. Oncol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0265","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sj.leu.2402825","article-title":"Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy","volume":"17","author":"Nakajima","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0270","first-page":"1481","article-title":"A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia","volume":"24","author":"Sumi","year":"2004","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcmd.2013.10.002_bb0275","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biochi.2007.07.011","article-title":"Targeting telomeres and telomerase","volume":"90","author":"De Cian","year":"2008","journal-title":"Biochimie"},{"key":"10.1016\/j.bcmd.2013.10.002_bb0280","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1582-4934.2010.01253.x","article-title":"Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives","volume":"15","author":"Bilsland","year":"2011","journal-title":"J. Cell. Mol. Med."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979613002313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979613002313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:29:14Z","timestamp":1761049754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979613002313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":56,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1079979613002313"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2013.10.002","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2013.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}